Trocar Pharma and its scientists have created a tissue-targeted, platform technology focused on allowing humans to survive in the harsh environment of outer space while simultaneously utilizing these same technologies to increase human longevity on Earth. 

​

Trocar's platform technology uniquely targets intercellular reactive oxygen species (ROS) with in vivo studies confirming the efficacy of our therapeutics in regenerating stem cells and increasing life span.

​

With over 50% of all deaths attributable to inflammation-related diseases and the overproduction of ROS leading to oxidative stress and chronic inflammation, our platform technology has a myriad of use cases.

 

Trocar's therapeutic strategy is focused on GI Acute Radiation Syndrome (GI ARS) and increasing human survival post exposure to lethal doses of radiation.